- Markets
- Healthcare
- ZENOTECH
ZENOTECH
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Zenotech Laboratories Names Sachin Laxmanappa Gavandare As CEO
Oct 23 (Reuters) - Zenotech Laboratories Ltd ZENL.BO:
ZENOTECH LABORATORIES - NAMES SACHIN LAXMANAPPA GAVANDARE AS CEO
Source text for Eikon: ID:nBSE6yHXgS
Further company coverage: ZENL.BO
(([email protected];))
Oct 23 (Reuters) - Zenotech Laboratories Ltd ZENL.BO:
ZENOTECH LABORATORIES - NAMES SACHIN LAXMANAPPA GAVANDARE AS CEO
Source text for Eikon: ID:nBSE6yHXgS
Further company coverage: ZENL.BO
(([email protected];))
Events:
Rights
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Zenotech Laboratorie do?
Zenotech Laboratories Ltd specializes in developing and manufacturing generic biopharmaceuticals to meet global medical needs. They offer services for generating and characterizing recombinant proteins, covering gene cloning to protein production.
Who are the competitors of Zenotech Laboratorie?
Zenotech Laboratorie major competitors are Vivo Bio Tech, Jeevan Scientific, Dishman Carbogen Amc, Sun Pharma Adv. Res, Syngene Internation., Suven Life Sciences, Hikal. Market Cap of Zenotech Laboratorie is ₹369 Crs. While the median market cap of its peers are ₹3,329 Crs.
Is Zenotech Laboratorie financially stable compared to its competitors?
Zenotech Laboratorie seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Zenotech Laboratorie pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Zenotech Laboratorie latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Zenotech Laboratorie allocated its funds?
Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments
How strong is Zenotech Laboratorie balance sheet?
Balance sheet of Zenotech Laboratorie is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Zenotech Laboratorie improving?
No, profit is decreasing. The profit of Zenotech Laboratorie is ₹4.99 Crs for TTM, ₹8.3 Crs for Mar 2024 and ₹11.59 Crs for Mar 2023.
Is the debt of Zenotech Laboratorie increasing or decreasing?
Yes, The debt of Zenotech Laboratorie is increasing. Latest debt of Zenotech Laboratorie is -₹21.92 Crs as of Sep-24. This is greater than Mar-24 when it was -₹39.37 Crs.
Is Zenotech Laboratorie stock expensive?
Yes, Zenotech Laboratorie is expensive. Latest PE of Zenotech Laboratorie is 73.84, while 3 year average PE is 38.73. Also latest EV/EBITDA of Zenotech Laboratorie is 27.78 while 3yr average is 25.09.
Has the share price of Zenotech Laboratorie grown faster than its competition?
Zenotech Laboratorie has given better returns compared to its competitors. Zenotech Laboratorie has grown at ~4.76% over the last 7yrs while peers have grown at a median rate of -3.7%
Is the promoter bullish about Zenotech Laboratorie?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Zenotech Laboratorie is 68.84% and last quarter promoter holding is 68.84%.
Are mutual funds buying/selling Zenotech Laboratorie?
There is Insufficient data to gauge this.